Condition: Locally Advanced or Metastatic Breast Cancer · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.
This description comes directly from the study's public registry record.
Shusen Wang · 0086-020-87343811 · wangshs@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Liuzhou people's Hospital | Liuzhou, Guangxi, China | Recruiting |
| Anyang Cancer Hospital | Anyang, He'nan, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang, He'nan, China | Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Harbin Medical University cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Xiangyang Cancer Hospital | Wuhan, Hubei, China | Recruiting |
| Jiangsu Cancer Hospital | Nanjing, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| Jilin Cancer Hospital | Changchun, Jilin, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| General Hospital of Ningxia Medical University | Yinchuan, Ningxia, China | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05860465